Background Several lines of evidence support the hypothesis that impaired functioning of the glutamatergic N-methyl-D-aspartate receptor (NMDAR) might be involved in the etiology of schizophrenia. NMDAR is activated by phosphorylation by Fyn, and there is also some evidence to suggest that abnormalities in Fyn functionality could also be involved in susceptibility to schizophrenia. In a recent weighted burden analysis of exome-sequenced schizophrenia cases and controls, we noted modest statistical evidence for an enrichment of rare, functional variants in FYN, GRIN1, and GRIN2B in schizophrenia cases.
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Aim To test the plausibility of the hypothesis that schizophrenia susceptibility might be associated with genetic variants predicted to cause impaired functioning of NMDAR, either directly or indirectly through impairment of the kinases that phosphorylate it.
Methods In an exome-sequenced sample of 4225 schizophrenia cases and 5834 controls, rare variants occurring in genes for the NMDAR subunits and for the kinases acting on it were annotated. The counts of disruptive and damaging variants were compared between cases and controls, and the distribution of amino acids affected by damaging variants was visualised in ProteinPaint and the RCSB Protein Data Bank. Special attention was paid to tyrosine residues subject to phosphorylation.
Results There was no suggestion that abnormalities of the serine-threonine kinases or of Src were associated with schizophrenia. Overall, three cases and no controls had a disruptive variant in GRIN2A and two cases and no controls had a disruptive variant in FYN. Moreover, 14 cases and three controls had damaging variants in FYN, and all the variants in controls affected amino acid residues in the N-terminal region outside of any known functional domains. By contrast, 10 variants in cases affected amino acids in functional domains, and in the 3D structure of Fyn, two of the amino acid substitutions, A376T and Q517E, were adjacent to each other. A total of eight cases and one control had damaging variants in GRIN1, but there was no obvious pattern with respect to particular functional domains being affected in this or other genes. A single case had a variant in GRIN2A affecting a well-supported phosphorylation site, Y943C, and three cases had a variant in FYN which produces an amino acid change, T216S, which lies two residues away from two adjacent well-supported phosphorylation sites. Aside from this, there was no suggestion that tyrosine phosphorylation sites in Fyn or NMDAR were affected.
Conclusion
The numbers of variants involved are too small for firm conclusions to be drawn. The results are consistent with the hypothesis that ∼ 0.5% of patients with schizophrenia have disruptive or damaging genetic variants, which could plausibly impair functioning of NMDAR directly or indirectly through impairing Fyn function. Psychiatr Genet 29:44-50 Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.
Introduction
Outside of the cerebellum, the glutamatergic N-methyl-Daspartate receptor (NMDAR) consists of a tetramer of two NR1 subunits, coded for by the gene GRIN1, and two NR2 units, either NR2A or NR2B, coded for by GRIN2A and GRIN2B (Chen and Roche, 2007) . Variants in these genes can lead to epilepsy, intellectual disability and other neuropsychiatric disorders (XiangWei et al., 2018) . As recently reviewed, there is evidence from a variety of sources to support the hypothesis that hypofunction of NMDAR may contribute to the pathophysiology of schizophrenia (Balu, 2016) . Phencyclidine, which is an NMDAR channel blocker, induces a psychotomimetic state that closely resembles schizophrenia and can produce not only positive symptoms of hallucinations and delusions but also formal thought disorder and negative symptoms (Javitt and Zukin, 1991) . Some Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website, www.psychgenetics.com. studies have found reduced levels of GRIN1 mRNA and/or NRl protein in different brain regions of patients with schizophrenia (Gao et al., 2000; Law and Deakin, 2001; Stan et al., 2015; Catts et al., 2016) . Patients with autoimmune NMDAR encephalitis can present with psychotic symptoms, memory deficits, and catatonic symptoms (Dalmau et al., 2011) , and patients with an initial diagnosis of schizophrenia are reported to have increased rates of NMDAR antibodies (Steiner et al., 2013) . GRIN2A was included in one of the 108 implicated regions in a large genome-wide association study of schizophrenia (Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014), and the set of genes coding for proteins associated with NMDAR was found to be enriched for both de-novo copy number variants and small de-novo mutations (Kirov et al., 2012; Fromer et al., 2014) . In the Swedish schizophrenia study including nearly 5000 exomesequenced schizophrenia cases, there was an enrichment of ultra-rare, singleton variants predicted to be gene disruptive among the set of genes encoding interactors with NMDAR (Genovese et al., 2016) . Overall, there are contributions to the genetic risk of schizophrenia from common variants, copy number variants, and rare coding variants , and it is quite possible that these might include variants within genes encoding for NMDAR.
A fundamental mechanism for regulating NMDAR function is by phosphorylation, which affects both the trafficking of the receptor and its channel properties, as has been reviewed in detail elsewhere (Chen and Roche, 2007) . The subunits contain many serine/threonine phosphorylation sites, which are substrates for protein kinases A, B and C; calcium/calmodulin-dependent protein kinase II; and casein kinase II. Phosphorylation of these sites can have a variety of effects on the pharmacological functioning of NMDAR. Separately, the subunits also contain tyrosine residues that are substrates for phosphorylation by protein tyrosine kinases, in particular Fyn and Src, and this can affect NMDAR function as well as trafficking and endocytosis so that tyrosine phosphorylation by these kinases serves to upregulate NMDAR (Ali and Salter, 2001 ). The Tyr 1325 residue of NR2A is most prominently phosphorylated in-vitro by Fyn, and mice engineered to have a homozygous Tyr-1325-Phe mutation to prevent the phosphorylation of this site are reported to show some antidepressant-like behavior (Taniguchi et al., 2009) . Fyn-deficient mice show an increased acoustic startle response under bright light, and this is accompanied by increased serotonergic and dopaminergic activity in the prefrontal cortex and limbic system (Hironaka et al., 2002) . Haloperidol injection activates Fyn in mice and increases NR2B phosphorylation, whereas Fyn-deficient mice are resistant to haloperidol-induced catalepsy (Hattori et al., 2006) . Alternative mRNA splicing with lower levels of Fyn protein has been reported to occur in patients with schizophrenia and their relatives (Hattori et al., 2009) , and in a recent GWAS of schizophrenia rs7757969, which lies in an intron of FYN, the gene that codes for Fyn, was significant at P = 4.8 × 10 − 8 (Li et al., 2017) . Of note, Fyn itself is subject to phosphorylation and is activated by autophosphorylation of a conserved residue, tyrosine 416 (Y416), a process which is subject to dopaminergic and cholinergic regulation (Mao and Wang, 2015) .
We carried out an analysis of the exome-sequenced Swedish schizophrenia cases and controls, but in contrast to the previously reported study (Genovese et al., 2016) , we did not restrict attention to only singleton variants predicted to completely disrupt gene functioning but included all rare variants, though with a weighting scheme to give higher weight to variants predicted to have a more deleterious effect . For this weighted burden analysis, the strength of evidence implicating each gene is summarized as the signed log P value (SLP), and we noted that the set of genes with most evidence for an excess of rare, damaging variants in schizophrenia cases was the set denoted 'FMRP targets' (gene set SLP = 7.1) and that within this set the most strongly implicated gene was FYN, with SLP = 3.4. Other genes within this set included GRIN1 (SLP = 1.7) and GRIN2B (SLP = 2.1).
These results suggested to us the possibility that genetic variants might increase susceptibility to schizophrenia by impairing the normal functioning of NMDAR through different mechanisms. This might be through variants within the genes coding for the NMDAR subunits or through variants in genes such as FYN whose products would normally upregulate NMDAR. Such variants might completely disrupt the functioning of the gene, by producing stop codons, frameshifts, or splice site changes. Alternatively, they might introduce amino acid changes that critically affected the functioning of the protein. In particular, a coding variant changing a tyrosine residue that was a target of Fyn might have a similar effect to a deleterious variant in FYN itself. Accordingly, we decided to investigate more closely the coding variants occurring in genes for the NMDAR subunits and the kinases acting on them.
Methods
We used the same data set as had been used in the previously reported ultra-rare variant and weighted burden analyses (Genovese et al., 2016; Curtis et al., 2018) , consisting of exome-sequenced Swedish patients of whom there were 4225 schizophrenia cases and 5834 controls. We restricted attention to the 23 genes that code for the subunits of the NMDAR protein and the kinases that are involved in its phosphorylation, as listed in Table 1 . Variants were annotated with using VEP, PolyPhen, and SIFT (Kumar et al., 2009; Adzhubei et al., 2013; McLaren et al., 2016) . We restricted attention to variants that were both rare, occurring in a total of no more than 10 case subjects [minor allele frequency (MAF) < 0.0005], and predicted to either completely disrupt gene functioning (frameshift, stop-gained and essential splice site variants) or be potentially damaging. Potentially damaging variants were defined as being nonsynonymous variants either predicted to be deleterious by SIFT or to be possibly/ probably damaging by PolyPhen (or both). Population frequencies for all variants studied were obtained from gnomAD (Lek et al., 2016) . For the damaging variants, we visualized the distribution of the altered amino acid residues across functional domains of the protein using the ProteinPaint web application provided at https://pecan.stjude. cloud/home (Zhou et al., 2016) . To assess whether damaging variants might disrupt phosphorylation sites, we used the information provided by PhosphoSitePlus (Hornbeck et al., 2015) . For each protein, this provides information regarding which residues are subject to phosphorylation and other modifications along with the number of references that support this modification from high-throughput and lowthroughput experiments, the latter being more reliable. For the assessment of the possible effect of variants on phosphorylation sites, we restricted attention to tyrosine residues in the NMDAR subunits and Fyn. To visualize the distribution of altered amino acid residues in the 3D structure of the protein, we obtained structures from the RCSB Protein Data Bank at http://www.rcsb.org (Berman et al., 2000) and colour-coded altered residues using the JSmol viewer provided there. As the preliminary results did not suggest that disturbance of serine-threonine kinase functioning was associated with schizophrenia, for the 3D studies, we restricted investigation to NMDAR, Fyn, and Src. Table 2 shows the summary results for the genes involved as obtained from the original weighted burden analysis. This shows that GRIN1, GRIN2B, and FYN have modestly positive SLP values, though as previously stated, none of the individual gene results are formally statistically significant. In this analysis, three disruptive mutations had been assigned to GRIN2B. However, on further examination of the downloaded VCF file, it transpired these were all in the same subject and reflected a single frameshift mutation which produced a sequence change that had been annotated as three separate frameshift mutations close to each other. Once this was corrected, there was one case and one control with a disruptive variant in GRIN2B and no excess of damaging variants in cases. Overall, two cases and no controls had a disruptive variant in FYN, and both GRIN1 and FYN had an excess of damaging variants in cases. Although GRIN2A produced only a very small SLP in the weighted burden analysis (0.14), three cases and no controls had a disruptive variant in this gene. By contrast, SRC had an excess of damaging variants in controls, and overall there was no suggestion that there was an excess of rare disruptive and damaging variants in cases in the genes coding for the serine-threonine kinases. Table 3 shows a detailed breakdown of the genotypes and amino acid changes in GRIN1, GRIN2A, GRIN2B, and FYN. The variant frequencies from gnomAD are shown for Finnish and non-Finish Europeans, and all variants were rare (MAF = 0.001 or less) in all other populations except The SLP is the signed log P value, indicating the overall level of support for association with schizophrenia obtained from the weighted burden analysis. For rare variants, occurring in no more than 10 case subjects, the total counts for gene-disruptive and gene-damaging variants in controls and cases are shown. CaMKII, calcium/calmodulin-dependent protein kinase II; NMDAR, N-methyl-Daspartate receptor; SLP, signed log P value. for the variant in FYN at 6:112041068, which has MAF = 0.002 in African Americans.
Results
As shown in Fig. 1 and Supplementary Fig. 1 (Supplemental digital content 1, http://links.lww.com/PG/A214 ) for almost all genes, the distribution of damaging variants across protein domains did not reveal any particular patterns and there was no marked tendency for a specific functional domain to be enriched for damaging variants in cases. NR1 has an excess of damaging variants in cases, and these are widely distributed. The only gene to show a pattern in the distribution of damaging variants was Fyn. As shown in Fig. 1d and Supplementary Fig. 1d (Supplemental digital content 1, http://links.lww.com/PG/A214 ) the three amino acid residues altered in controls all occurred in the N-terminal region of the protein to which no functional domain is assigned. By contrast, 10 cases had a genetic variant that would alter an amino acid residue in one of the functional domains.
Regarding phosphorylation sites, experimental support for each site can be quantified by the number of supporting references (high throughput/low throughput). The best supported site in NR2A is Y943 (134/2), and one case has a Y943C variant. In NR2B, three cases and two controls have Y1371C, but this site has only modest support (11/1). One control has a Y30C substitution in Fyn, but this site has only low support (0/1). No other well-supported sites were directly affected. However, it may be worth noting that there were two well-supported sites adjacent to each other in Fyn, Y213 (1800/1) and Y214 (671/1), and that three cases have a T216S substitution. It is not inconceivable that this change two residues away might be sufficient to disrupt recognition of the site and hence impair phosphorylation.
In general, examination of the 3D localization of the substitutions did not yield any new insights. However, using model 2DQ7 (Kinoshita et al., 2006) for Fyn did reveal that A376T (observed in two cases) and Q517E (observed in one case) end up adjacent to each other in the folded protein. This is illustrated in Supplementary Fig. 2 (Supplemental digital content 1, http://links.lww.com/PG/A214).
On examining the distribution of variants across patients in GRIN1, GRIN2A, GRIN2B, and FYN, it emerged that one case had a damaging variant in GRIN1 and a frameshift variant in GRIN2A, whereas another case had a damaging variant in GRIN1 and in GRIN2B. No other case subjects had more than one variant in these genes.
Discussion
The number of variants involved is too small for any definite conclusions to be reached. However, there are a few points of interest. First, there is no evidence to implicate disruption of serine-threonine phosphorylation or disruption of tyrosine phosphorylation by Src. Thus, if impaired tyrosine phosphorylation of NMDAR has any relevance to schizophrenia etiology, this seems likely to be specific to Fyn rather than Src. It is also not the case that amino acid substitutions in NMDAR preventing phosphorylation occur commonly in schizophrenia -we observe this in only a single case out of 4225 -nor is there strong evidence that variants interfering with Fyn autophosphorylation occur commonly. We see no definite examples of this, and the closest we come to any support for this is the observation that three cases have an amino acid substitution two residues away from a tyrosine residue that is well-supported as a phosphorylation site. We do observe that three cases and no controls have disrupting variants in GRIN2A and that eight cases and one control have damaging variants in GRIN1. A total of 14 cases and three controls have damaging variants in FYN, but if we restrict attention to functional domains of the protein, this applies to 10 cases and no control. Aside from that, we cannot discern any obvious pattern to the distribution of damaging variants. Overall, these possibly relevant variants were seen in ∼0.5% of the cases.
These results are perfectly consistent with the hypothesis that the risk of schizophrenia may be increased by genetic variants impairing NMDAR functioning, either directly or by reducing phosphorylation by Fyn. However, this study provides at best only modest further support. It is hoped that the situation may become clearer as larger numbers of cases are sequenced. It might also be helpful to carry out functional studies to determine the effect of these variants in vitro and in vivo. This approach demonstrates ways in which additional information of possible biological relevance can be mined from sequencing studies.
